Press Release FeedGet the RSS feed
Menu

Business Wire

LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX

Business Wire

Advancing AI Infrastructure Value Chain Through Integrated Power Management and Cooling Technologies

TAIPEI, Taiwan, September 03, 2026--LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. ("DCX Liquid Cooling Systems"), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI infrastructure and next-generation high-density computing market.

The accelerating adoption of AI applications is driving unprecedented rack power densities, making liquid cooling a critical enabling technology for future-ready data centers and high-performance computing. Founded in 2019 and headquartered in Warsaw, Poland, DCX Liquid Cooling Systems has established itself as a leading innovator in direct-to-chip and immersion liquid cooling, with advanced design and integration capabilities in liquid cooling infrastructure for data centers, offering a complete portfolio ranging from enterprise-level coolant distribution units (600kW–2.6MW) to hyperscale-class facility coolant distribution units (up to 16MW), as well as cold plates, rack manifolds and modular data center systems. Through this strategic partnership, LITEON and DCX Liquid Cooling Systems will expand collaboration across product development, engineering innovation, manufacturing scale-up, and global go-to-market initiatives. The companies will jointly develop integrated power-and-cooling platforms designed to address the increasing performance and efficiency demands of the hyperscale data center customers worldwide.

"AI has become a key force reshaping industries, and data center infrastructure is a critical foundation for unlocking AI's full potential," said Tom Soong, Chairman of LITEON. "As we continue to invest in advanced technologies, this strategic investment further strengthens LITEON's position across the AI data center value chain. Through this partnership, we look forward to advancing innovation and creating new possibilities in the rapidly expanding AI market..."

  1. FinanceFaraday Future Intelligent Electric Inc.Faraday Future Announces YT Jia’s Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26This week's Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 26. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) will hold its Listing Ceremony and Investor Day on October 26. FFR management will outline the company's future strategic direction and business plans and engage with in
  2. RetailRetail Loss Is Bigger Than External Theft: New IHL Group and Sensormatic Solutions Research Reveals Broader Sources of LossExternal theft, including organized retail crime, is the largest single source of loss at 25%, but three-quarters of loss dollars occur elsewhere All sources of loss tracked in the study are on the rise, with more than half (54%) of retailers reporting an increase in each area BOCA RATON, Fla., October 25, 2026 --( BUSINE
  3. HealthcareSummit Therapeutics Inc.Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaFirst Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in BTC Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 25% Compared to Durvalumab Plus Chemotherapy; OS Hazard Ratio 0.75
  4. HealthcareSonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this setting WILMINGTON, Del., October 25, 2026--Positive results from the CLARITY-Gastric01 globa
  5. HealthcareGenentechGenentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung CancerDivarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 1
  6. Biotech & pharmaTAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSOTAGRISSO plus savolitinib extended median overall survival by nearly five months SAFFRON is first global Phase III trial to show significant progression-free and overall survival benefit in this setting, reinforcing TAGRISSO as backbone therapy across EGFRm lung cancer WILMINGTON, Del., October 25, 2026 --( BUSINESS WIRE